Atomoxetine

@article{Simpson2012Atomoxetine,
  title={Atomoxetine},
  author={Dene Simpson and Greg L. Plosker},
  journal={Drugs},
  year={2012},
  volume={64},
  pages={205-222},
  url={https://api.semanticscholar.org/CorpusID:195692609}
}
Atomoxetine is an effective and generally well tolerated treatment for adults with ADHD and is the first ADHD treatment to be approved specifically for adult use based on its efficacy in well controlled adult trials.
View on Springer Nature
ncbi.nlm.nih.gov
86 Citations
Highly Influential Citations
8
Background Citations
28
Methods Citations
2
Results Citations
3

86 Citations

A Review on Atomoxetine in the Treatment of Attention Deficit HyperactivityDisorder

Atomoxetine is a first non-stimulant and the first drug to be licensed for the treatment of Attention Deficit Hyperactivity Disorder in adults and children and has been shown to be well tolerated in most of the patients.

Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study

There was significant resolution of symptoms of all outcome measures, including the symptoms of anxiety, as shown by changes from baseline in HAM-A, ASRS-v1.1, and CGI at 12 weeks (P < .001).

Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study

The initial findings of the study show that reboxetine may constitute an effective tool for long-term treatment of children with ADHD who present poor response or poor tolerance to initial treatment with methylphenidate.

Atomoxetine Attenuates Dextroamphetamine Effects in Humans

Atomoxetine's capacity to attenuate some of the physiological and subjective responses to dextroamphetamine supports its potential use for stimulant addiction.

Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects

Effectiveness Of Atomoxetine For Cognitive Function In Methamphetamine Dependent Patients; A Randomized Controlled Trial

Background: A substantial body of evidences indicates that methamphetamine abuse can lead to persistent and serious cognitive dysfunction. Preclinical studies and early pilot clinical investigations…

Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL)

The AAQoL was responsive to change in symptoms of ADHD, and it appears to be a useful outcome measure for treatments of ADHD in adults.

Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.

Atomoxetine Used Adjunctively With Selective Serotonin Reuptake Inhibitors to Treat Depression.

It is pointed out that newer dual-action antidepressants mediating serotonin and norepinephrine have increased in scientific and clinical interest and may reduce the symptoms of depression more effectively than the selective serotonin reuptake inhibitors (SSRIs).

Atomoxetine Efficacy in Methamphetamine Dependence during Methadone Maintenance Therapy.

This study confirms the safety and clinical tolerance of atomoxetine, and its appropriate efficacy in suppressing METH craving and possible potential effects on its treatment.
...

31 References

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.

This preliminary study showed that tomoxetine was effective in treating adult ADHD and was well tolerated, and these promising results provide support for further studies of tomoxettine over an extended period of treatment.

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

Two studies early in its development confirmed that atomoxetine, a specific and selective inhibitor of noradrenergic uptake, was effective for the treatment of children with ADHD and was found to be well tolerated.

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms.

Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults

While atomxetine has noradrenergic activity, increases in pulse and blood pressure were small and of little, if any, clinical significance, and atomoxetine was well tolerated in short- and long-term studies.

Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder

Atomoxetine (Strattera™, Eli Lilly & Co.) is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). So far,…

Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study

Once-daily administration of atomoxetine is an effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD) as assessed by investigator, parent, and teacher ratings.

Pharmacotherapy of Attention Deficit Hyperactivity Disorder in Adults

The majority of studies suggest that stimulants are the most effective available agents for adults with ADHD, and these drugs remain the treatment of choice.

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users.

Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder

The findings from this study have been generalised to adults that also have ADHD, particularly in cases where there is a well-defined longitudinal history dating back to early childhood.

Related Papers

Showing 1 through 3 of 0 Related Papers